User: Guest  Login
Title:

Suppression of Endothelial Cell FAK Expression Reduces Pancreatic Ductal Adenocarcinoma Metastasis after Gemcitabine Treatment.

Document type:
Journal Article; Research Support, Non-U.S. Gov't
Author(s):
Roy-Luzarraga, Marina; Reynolds, Louise E; de Luxán-Delgado, Beatriz; Maiques, Oscar; Wisniewski, Laura; Newport, Emma; Rajeeve, Vinothini; Drake, Rebecca J G; Gómez-Escudero, Jesús; Richards, Frances M; Weller, Céline; Dormann, Christof; Meng, Ya-Ming; Vermeulen, Peter B; Saur, Dieter; Sanz-Moreno, Victoria; Wong, Ping-Pui; Géraud, Cyrill; Cutillas, Pedro R; Hodivala-Dilke, Kairbaan
Abstract:
UNLABELLED: Despite substantial advances in the treatment of solid cancers, resistance to therapy remains a major obstacle to prolonged progression-free survival. Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancers, with a high level of liver metastasis. Primary PDAC is highly hypoxic, and metastases are resistant to first-line treatment, including gemcitabine. Recent studies have indicated that endothelial cell (EC) focal adhesion kinase (FAK) regulates DNA-damaging th...     »
Journal title abbreviation:
Cancer Res
Year:
2022
Journal volume:
82
Journal issue:
10
Pages contribution:
1909-1925
Fulltext / DOI:
doi:10.1158/0008-5472.CAN-20-3807
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/35350066
Print-ISSN:
0008-5472
TUM Institution:
Lehrstuhl für Experimentelle Tumortherapie (Prof. Saur)
 BibTeX